CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free ...
Daily1d
AstraZeneca Tagrisso recommended for approval in EU by CHMP for patients with unresectable EGFR mutated lung cancer
Cambridge: AstraZeneca's Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the ...
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
EuropaWire1d
AstraZeneca’s Tagrisso Receives EU Recommendation as First Targeted Therapy for Unresectable EGFR-Mutated Lung Cancer
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...
Pharmabiz1d
European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer
European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer ...
rnz2d
Cancer patient still self-funding life extending drug
Lung cancer drug Tagrisso or Osimertinib was supposed to be one of the first rolled out. A relief for former taxi driver and cancer patient Akhil Chaudhary; he's been funding an average of $1300 a ...
Targeted Oncology5d
Adverse Event Management: Amivantamab
Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, ...
News Medical5d
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths
Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...
policymed.com6d
Oncology Unscripted with John Marshall, MD: Are You Overdosing Your Patients? Revisiting Dosing Practices
In the latest episode of Oncology Unscripted, Dr. John Marshall addresses critical issues concerning the dosing practices in oncology, particularly questioning the prevailing approach of using maximum ...